Alec Stranahan
Stock Analyst at B of A Securities
(0.79)
# 4,023
Out of 5,112 analysts
32
Total ratings
40%
Success rate
-25.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $235.80 | +8.14% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.50 | +27.27% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $15.80 | -24.05% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $3.64 | -72.53% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $6.53 | +7.20% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $25.60 | +64.06% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $8.76 | +185.39% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.62 | +579.01% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.59 | +131.66% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.37 | +532.91% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $76.74 | -28.33% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $31.13 | -80.73% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $235.80
Upside: +8.14%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.50
Upside: +27.27%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $15.80
Upside: -24.05%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $3.64
Upside: -72.53%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $6.53
Upside: +7.20%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $25.60
Upside: +64.06%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $8.76
Upside: +185.39%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.62
Upside: +579.01%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.59
Upside: +131.66%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.37
Upside: +532.91%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $76.74
Upside: -28.33%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $31.13
Upside: -80.73%